ArticleTransplantation direct2026
Reactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Background: Solid organ transplant (SOT) recipients are at high risk for severe respiratory syncytial virus (RSV). While RSV vaccine immunogenicity data in transplant populations are emerging, questions remain regarding the magnitude and durability of responses, cellular immunity, and determinants of decreased response. Methods: We conducted a prospective, single-center cohort study evaluating RSV vaccine reactogenicity and immunogenicity in SOT recipients compared with healthy controls. Serum was collected pre-vaccination and at 1, 3, and 6 mo post-vaccine to measure anti-fusion glycoprotein antibodies to RSV A and B and anti-nucleocapsid antibodies as a marker of natural infection. Peripheral blood mononuclear cells were collected from a subset for RSV-fusion (F)-specific cellular analyses. Results: Forty-three SOT recipients (median age, 65) and 16 controls were enrolled (from October 2023 to January 2024). Mild reactogenicity occurred in ~25% of participants, with no severe events. In SOT recipients, anti-fusion glycoprotein IgG, RSV-F-specific CD4 Conclusions: RSV vaccination was well tolerated and immunogenic in SOT recipients. Further research should optimize vaccination strategies and ideal timing for booster doses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.